Study of Artesunate in Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Metastatic Breast CancerLocally Advanced Breast Cancer
Interventions
DRUG

artesunate

add-on therapy with daily single oral doses of 100, 150 or 200 mg of artesunate

Trial Locations (1)

D-69120

Complementary and Integrative Medicine, Dep. Gyn. Endocrinology, Women's Hospital, University of Heidelberg, Heidelberg

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Hector-Stiftung

OTHER

collaborator

Dafra Pharma

INDUSTRY

collaborator

Monika-Kutzner Stiftung, Berlin, Germany

UNKNOWN

collaborator

HEIFAN-Heidelberger Förderverein d. Ambulanz f. Naturheilkunde eV, Heidelberg, Germany

UNKNOWN

lead

Heidelberg University

OTHER

NCT00764036 - Study of Artesunate in Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter